CYTK
Cytokinetics, Incorporated
NASDAQ · USHealthcareBiotechnology
$79.11-1.33%
Price as of Jul 20, 2026
CYTK capital
Cytokinetics, Incorporated capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- -1.56x
- Net debt / equity
- -1.40x
- Debt / assets
- 1.01x
- Debt / EBITDA
- -1.75x
- Net debt / EBITDA
- -1.58x
Liquidity & coverage
- Current ratio
- 4.21x
- Quick ratio
- 4.21x
- Cash ratio
- 4.11x
- Interest coverage
- -5.60x
- EBITDA / interest
- -6.43x
- Working capital
- $640.3M
Cash & dividend
- FCF / debt
- -0.43x
- Cash flow / debt
- -0.41x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.